Background: Pelvic organ prolapse (POP) significantly impacts women’s quality of life, especially in postmenopausal patients. Although laparoscopic sacrocolpopexy (LSC) is the gold standard for advanced apical prolapse, its complexity and risk of complications have led to alternative approaches like laparoscopic lateral suspension (LLS), a minimally invasive technique with promising results. Methods: A comprehensive search using PubMed databases was performed. The search was conducted from June 2024 to September 2024. The search string used was as follows: (pelvic organ prolapse) AND (lateral suspension) OR (laparoscopic lateral suspension). We included randomized controlled trials, prospective cohort studies, prospective observational studies, and case studies. We excluded retrospective studies, small case series, case reports, and articles not published in English. All selected articles were screened based on the titles and abstracts. Relevant data were extracted and tabulated. Results: An overall number of 12 studies were included in our analysis. LLS demonstrated high anatomical success rates: 91.15% for the anterior, 94.95% for the central, and 86.55% for the posterior compartments. The randomized controlled studies exhibit comparable effectiveness between both methods (LLS vs. LSC) and LLS appears to be the best option for anterior repair or anterior–apical repair. Patient satisfaction rates exceeded 90%, with reduced operative times (123 ± 33 min and 193 ± 55.6 min for ALS and ASC, respectively). According to the Claiven–Dindo scale, 0.17% of postoperative complications were graded more than III. The rate of mesh erosion was 0% to 10%. The technique showed particular benefit for uterine preservation and in obese patients but was less effective for severe posterior prolapse. Conclusions: Laparoscopic lateral suspension offers a safe, effective alternative for POP management, with significant anatomical and functional benefits. Its minimally invasive nature, shorter surgery time, and high satisfaction rates make it suitable for tailored patient care. Further studies should standardize evaluation metrics and assess long-term outcomes. The review was not registered. No funding was received. The authors declare no competing interests.

Background: Serum biomarkers such as Carcinoma Antigen 125 (CA125) and Human Epididymis Protein 4 (HE4) are widely used in the diagnosis and prognosis of gynecological malignancies. Serum biomarkers such as CA125 and HE4 represent essential tools in improving early detection, risk stratification, and therapeutic decision-making for gynecological malignancies. However, their role in identifying uterine sarcomas remains debated. This systematic review and case series aims to examine the diagnostic and prognostic significance of CA125 and HE4 in uterine sarcomas. Methods: A systematic review was performed on studies investigating serum CA125 and HE4 levels in uterine sarcomas. A case series of all uterine sarcomas treated at the Campus Bio-Medico Gynecology Unit of Rome from 2010 to 2020 was analyzed. Results: The analysis of the 11 selected studies allowed us to investigate the role of CA125 in uterine sarcomas. No studies analyzing the role of HE4 in monitoring the disease were found. A total of 16 patients with confirmed uterine leiomyosarcoma were included in our case series. Conclusions: Neither CA125 nor HE4 can currently be considered definitive biomarkers for the diagnosis of uterine leiomyosarcomas. However, they may serve as useful adjuncts in the differential diagnosis between leiomyomas and leiomyosarcomas, particularly in reproductive-age patients.

Background: Cervical cancer ranks among the most prevalent tumors in low-income countries, with the Pap test as one of the primary screening tools. The Pap smear detects abnormal cells, the CLART test identifies specific HPV genotypes, and HPV self-sampling allows for self-collected HPV testing. This study aimed to evaluate the feasibility of the first smartphone-based health device for home-collection HPV testing. Methods: Enrolled patients during the gynecological examination underwent three different samplings: Pap smear, HPV DNA genotyping test CLART, and vaginal HPV-Selfy swab. Each patient received a kit including an activation code, vaginal swab, and instructions. After performing the self-sample, patients returned the kit to our laboratory. Both the samples collected by the gynecologist and those collected by the patients themselves were analyzed. Results: A total of 277 patients were enrolled, with 226 self-collected swabs received for analysis. The assay yielded valid results for both self-collected and clinician-collected swabs in 190 patients. When comparing these results with paired clinician-taken vaginal swabs, we observed an agreement of 95.2% (Cohen’s Kappa: 0.845). We report an agreement of 93.7% (Cohen’s Kappa: 0.798). Conclusions: The study demonstrated the feasibility of HPV-Selfy as a complementary tool in cervical cancer screening, especially where adherence to traditional surveillance is low.

Introduction: Transobturator midurethral slings (MUSs) are commonly used to treat female stress urinary incontinence (SUI). Despite their high success rates, postoperative complications such as voiding dysfunction (VD) and de novo overactive bladder (OAB) symptoms may affect quality of life (QoL). This study aims to evaluate patient-reported outcomes regarding bladder dysfunction (VD and OAB) and SUI resolution. Methods: Patients undergoing transvaginal tension-free vaginal tape-obturator (TVT-O) for SUI without detrusor overactivity were enrolled from April 2018 to April 2023. Final 12-month follow-up was completed in April 2024. Follow-up at 6 and 12 months included physical examination, stress tests, and a 3-day voiding diary. The Urinary Symptom Profile (USP) questionnaire was administered at 12 months. A VAS score evaluated the subjective bother of voiding dysfunction. Objective cure was defined as a negative stress test at follow-up. Changes in daily leakage episodes were assessed using the 3-day voiding diary. Results: Ninety-two patients were enrolled, of whom eight-nine completed the 6- and 12-month follow-up and were included in the final analysis. The objective cure rate was, respectively, 93% at 6 months and 89% at 12 months. The USP questionnaire administered at 12 months showed that the SUI domain score was 0 in 80.9% of patients. De novo urgency was reported in 44% of patients. Urge incontinence and nocturia occurred, respectively, in 33% and 8% of patients. Patient-reported voiding symptoms, defined as LS $\ge 1$, were observed in 58.4% of patients. Among patients with LS $\ge 1$, 38/52 (73.1%) reported tolerable bother (VAS < 5), whereas 14/52 (26.9%) reported clinically important or intolerable bother (VAS $\ge 5$). Conclusions: TVT-O was associated with a high objective cure rate; however, patient-reported OAB and voiding symptoms were common at 12 months. These findings support a more comprehensive informed consent process for patients undergoing TVT-O surgery in order to increase patient awareness of the potential development of OAB and VD following the surgical procedure.